BioTime Adds Five New Stem Cell Lines to Its
May 27, 2010 08:48 AM Eastern Daylight Time
ALAMEDA, Calif.--(EON: Enhanced Online News)--BioTime, Inc. (AMEX:BTIM) announced today that on June
1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines
were developed using BioTime’s ACTCellerate™ technology. These highly purified, novel, and scalable cell lines
are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully
developed cells. The new lines will include W10 with markers of smooth muscle progenitors, RASMO12 with
unique markers associated with the kidney, U31 with markers associated with the neurotransmitter dopamine useful
in research in Parkinson’s disease and diseases of the autonomic nervous system, as well as the lines SK11, EN1,
and 7SMOO7, properties of which will be disclosed on product launch. BioTime CEO Dr. Michael West will
discuss these new products as part of a presentation today at the GTCbio 6th Annual Stem Cell Research &
Therapeutics Conference in Boston, Massachusetts. These new cell lines may be purchased beginning June 1, 2010,
and additional information about the products may be found, at http://www.embryome.com/products.htm.
Dr. West’s presentation at the GTCbio Conference will focus on stem cell differentiation and will describe BioTime’s
recent efforts to generate highly purified, diverse, and scalable embryonic progenitor (EP) cell types for potential use
in human cell therapy, including six cell types with potential use in orthopedic disease. A complete abstract of Dr.
West’s presentation is available on the conference website at www.gtcbio.com, and a copy of the presentation will
be available on BioTime’s website at www.biotimeinc.com.
The annual GTCbio Stem Cell Research & Therapeutics Conference provides leading-edge information on
developments in all areas of stem cell research, including the biology, medicine, applications, re